| Structural Genomics Consortium

Antibody characterization is critical to enhance reproducibility in biomedical research.

Read more about Antibody characterization is critical to enhance reproducibility in biomedical research.

Screening of a kinase inhibitor library identified novel targetable kinase pathways in triple-negative breast cancer.

Read more about Screening of a kinase inhibitor library identified novel targetable kinase pathways in triple-negative breast cancer.

A guide to selecting high-performing antibodies for Synaptotagmin-1 (Uniprot ID P21579) for use in western blot, immunoprecipitation, immunofluorescence and flow cytometry.

Read more about A guide to selecting high-performing antibodies for Synaptotagmin-1 (Uniprot ID P21579) for use in western blot, immunoprecipitation, immunofluorescence and flow cytometry.

Chemical coverage of human biological pathways.

Read more about Chemical coverage of human biological pathways.

Inhibition of bromodomain and extra-terminal proteins targets constitutively active NFκB and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC.

Read more about Inhibition of bromodomain and extra-terminal proteins targets constitutively active NFκB and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC.

Autoinhibition of ubiquitin-specific protease 8: insights into domain interactions and mechanisms of regulation.

Read more about Autoinhibition of ubiquitin-specific protease 8: insights into domain interactions and mechanisms of regulation.

A guide to selecting high-performing antibodies for Protein-glutamine gamma-glutamyltransferase 2 (TGM2) for use in western blot, immunoprecipitation and immunofluorescence.

Read more about A guide to selecting high-performing antibodies for Protein-glutamine gamma-glutamyltransferase 2 (TGM2) for use in western blot, immunoprecipitation and immunofluorescence.

A chemical screen identifies PRMT5 as a therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancer.

Read more about A chemical screen identifies PRMT5 as a therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancer.

Protein: MAP1LC3B

PDB ID: 8Q53

Deposition Date: Tuesday 8th August 2023

Authors: Kumar, A., Knapp, S.

Protein: JMJD1C

PDB ID: 9GDK

Deposition Date: Monday 5th August 2024

Authors: Fairhead, M., Strain-Damerell, C., Ye, M., Mackinnon, S.R., Pinkas, D., MacLean, E.M., Koekemoer, L., Damerell, D., Krojer, T., Arrowsmith, C.H., Edwards, A., Bountra, C., Yue, W., Burgess-Brown, N., Marsden, B., von Delft, F.